STIM (neurostar.com) צמיחת רווח למניה השנה

Neuronetics, Inc. (STIM) is expanding its business selling neuron stimulation systems, supplementing revenue with high-margin software. The shift in earnings per share compared to last year illustrates the market response, fixing the metric's value at 50.80. Success is based on the uniqueness of NeuroStar in treating depression, while the growth of the installed equipment base activates operating leverage through the sale of session cards.

To assess the return on capital for Neuronetics, Inc. (STIM), the balance between operational efficiency and the pressure of marketing expenses is critical. The YoY net income per share growth trend reflects the business's ability to scale earnings per share despite competition from pharmacology and the risks of reduced insurance reimbursements. Growth in this indicator confirms the resilience of the business model and the effectiveness of cost management.